Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$471.85 USD

471.85
1,399,486

+1.77 (0.38%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $472.00 +0.15 (0.03%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance

by Zacks Equity Research

DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.

    Zacks Equity Research

    Luminex (LMNX) Misses on Earnings in Q2, Margins Contract

    by Zacks Equity Research

    Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.

      Zacks Equity Research

      Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag

      by Zacks Equity Research

      We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.

        Zacks Equity Research

        Henry Schein's (HSIC) Q2 Earnings Beat, '18 EPS View Up

        by Zacks Equity Research

        All four of Henry Schein's (HSIC) operating segments recorded strong year-over-year growth in Q2.

          Zacks Equity Research

          Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates

          by Zacks Equity Research

          Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.

            Zacks Equity Research

            Cardinal Health (CAH) Surpasses Earnings Estimates in Q4

            by Zacks Equity Research

            Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.

              Zacks Equity Research

              Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand

              by Zacks Equity Research

              Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.

                Zacks Equity Research

                Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates

                by Zacks Equity Research

                Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.

                  Zacks Equity Research

                  Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y

                  by Zacks Equity Research

                  Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.

                    Zacks Equity Research

                    Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates

                    by Zacks Equity Research

                    We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q2, driven by solid performances in the United States and internationally.

                      Zacks Equity Research

                      ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth

                      by Zacks Equity Research

                      ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.

                        Zacks Equity Research

                        Pacific Biosciences (PACB) Loss In Line With Estimates in Q2

                        by Zacks Equity Research

                        Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.

                          Zacks Equity Research

                          DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View

                          by Zacks Equity Research

                          Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.

                            Zacks Equity Research

                            Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid

                            by Zacks Equity Research

                            Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.

                              Zacks Equity Research

                              CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance

                              by Zacks Equity Research

                              CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.

                                Zacks Equity Research

                                Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance

                                by Zacks Equity Research

                                Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.

                                  Zacks Equity Research

                                  DaVita (DVA) Beats Earnings and Revenue Estimates in Q2

                                  by Zacks Equity Research

                                  Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q2.

                                    Zacks Equity Research

                                    Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3

                                    by Zacks Equity Research

                                    Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.

                                      Zacks Equity Research

                                      PRA Health's (PRAH) Q2 Earnings Top, Revenues Lag Estimates

                                      by Zacks Equity Research

                                      PRA Health (PRAH) sees year-over-year double-digit growth in earnings, revenues and net new business in Q2. However, increasing labor-related costs in the Clinical Research wing is a concern.

                                        Zacks Equity Research

                                        Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall

                                        by Zacks Equity Research

                                        Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.

                                          Zacks Equity Research

                                          AmerisourceBergen (ABC) Beats on Q3 Earnings & Revenues

                                          by Zacks Equity Research

                                          AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q3.

                                            Zacks Equity Research

                                            PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up

                                            by Zacks Equity Research

                                            Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.

                                              Zacks Equity Research

                                              IDEXX Laboratories (IDXX) Beats on Q2 Earnings, EPS View Up

                                              by Zacks Equity Research

                                              IDEXX Laboratories' (IDXX) stellar performance in Q2 was driven by strong sales at the CAG business.

                                                Zacks Equity Research

                                                NuVasive (NUVA) Q2 Earnings Meet Estimates, EPS View Down

                                                by Zacks Equity Research

                                                NuVasive (NUVA) expects robust demand for recently-launched products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market.

                                                  Zacks Equity Research

                                                  Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips

                                                  by Zacks Equity Research

                                                  At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.